Thirteen Poster Abstracts Chronicling The Clinical Use, Cost Effectiveness And Accelerated Healing Results of MiMedx Products to be Presented by VA Physicians at Desert Foot Conference

MARIETTA, Ga., Nov. 18, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG) announced today that fourteen poster abstracts chronicling the Company's dehydrated human amnion/chorion membrane (dHACM) allografts to be clinically effective and cost effective in the healing of chronic wounds, difficult lower extremity wounds that have failed prior wound treatment modalities, challenging surgical wounds, chronic neuropathic wounds, wounds threatening the loss of limbs, and other hard-to-heal wounds will be presented at the 11^th Annual Desert Foot High Risk Diabetic Foot Conference in Phoenix, Arizona, beginning November 19, 2014, and concluding on November 21, 2014. The abstracts describe the results of independent case studies undertaken by the presenters.

MiMedx, the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, will also host a workshop for Podiatrists and residents with noted Key Opinion Leaders speaking on their professional experiences using MiMedx dHACM allografts in the treatment of difficult wounds.

Abstracts chronicling independent case studies and respective conclusions relative to MiMedx dHACM are:

• Abstract authored by Joseph Terebessy, DPM, concludes that dHACM is both a clinically effective and cost effective wound treatment in patients with chronic wounds of varying etiology.
• Abstract authored Robin Johnson, DPM, concluded that dHACM is a clinical and cost effective option with increased rates of healing, fewer grafts per healed wound and reduced costs vs. human fibroblast-derived dermal substitute.
• Abstract authored by Hannah Park, DPM, et al, concludes dHACM, with its ability to regulate cell proliferation, inflammation and metalloproteinase activity is an effective treatment for these challenging hypergranular wounds secondary to surgical dehiscence.
• Abstract authored by Darshan Nagesh, DPM, et al, concluded dHACM can significantly expedite healing in different types of refractory wounds concomitantly while addressing the underlying etiology of the wounds.
• Abstract authored by William Chagares, DPM, et al, concluded that dHACM availability in different sizes in relation to wound size allows for minimal product wastage; and dHACM is clinically efficacious, cost-effective and simplifies the storage and application process of advance care technology.
• Abstract authored by Patrick Sanchez, DPM, et al, concludes that dHACM plays an integral role in limb salvage efforts of high-risk diabetic patients and there were no adverse reactions to the therapy.
• Abstract authored by Karen Lorne, DPM, concluded dHACM is both a clinically effective and cost effective wound treatment in patients with chronic neuropathic wounds.
• Abstract authored by Robin Lenz, DPM, et al, reached the conclusion that dHACM helps heal chronic wounds, and with the proper offloading in a total contact cast, the healing process can be further optimized.
• Abstract authored by Kristie Taddie, DPM, et al, concluded that dHACM has shown to be an effective alternative for patients with difficult lower extremity wounds that have failed prior wound treatment modalities, while decreasing product wastage.
• Abstract authored by Alberto Abrebaya, DPM, et al, reached the following conclusions: the treatment of wounds of mixed etiopathogenesis with dHACM appears to be effective for accelerated healing rates of chronic DFU, traumatic and other types of lower extremity ulcerations; and the mean healing rates and application interval lengths appear to closely approximate the already published data on the dHACM allografts.
• Abstract authored by Lisa Maree Harmon, ANP-BC, MSN, et al, concluded that dHACM allograft is an effective treatment for the use in lower extremity chronic wound injuries, ulcers and other types of pressure induced ulcers of varying etiology.
• Abstract authored by Christopher Bromley, DPM, concludes dHACM allograft offers a cost effective wound healing modality in diabetic wound closure.
• Abstract authored by Laura Heath, DPM, PGY-3, concluded that dHACM is an option for treating diabetic wounds as well as venous, traumatic or post-operative wounds.

The workshop to be hosted by MiMedx is entitled Surgical and Wound Care Applications of EpiFix® and AmnioFix® dehydrated Human Amnion/Chorion Membrane (dHACM) allografts. It will be a hands-on workshop for podiatrists and residents to learn more about the clinical applications and science behind the Company's products. Chester Nava, DPM ; Dolores Farrer, DPM; Donna Becker, MSN, ACNP-BC; Laura Heath, DPM (Resident); and Devin Bland, DPM (Resident) will present and detail the mechanisms of action of PURION® Processed dHACM allografts and applications for wound healing. In these sessions, the speakers will also review surgical applications of dHACM allografts for varying podiatric procedures, and participants will be able to have hands-on experience with the allografts.

MiMedx is exhibiting at the conference in booth #15.

About MiMedx

MiMedx® is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane.  "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself.  Our biomaterial platform technologies include AmnioFix® and EpiFix®, our tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through our donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx® is the leading supplier of amniotic tissue, having supplied over 300,000 allografts to date for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

SOURCE MiMedx Group, Inc.

Related Links

http://www.mimedx.com